Fengtao You
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fengtao You has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Gangli An
Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China
1 shared publication - Hai Wu
PersonGen BioTherapeutics (Suzhou) Co., Ltd. Suzhou China
1 shared publication - Lin Yang
Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China
1 shared publication - Nan Yang
PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China
1 shared publication - Renyuxue Ma
Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection Soochow University Suzhou China
1 shared publication - Shuaiyu Tian
Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection Soochow University Suzhou China
1 shared publication
Latest Publications
- Open Access
- 6 September 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (1) , 64-74
Enhanced efficacy of CD19/CD22 bispecific CAR‐T cells with EAAAK linker on B‐cell malignancies
Objectives: Despite the great success of CD19 CAR‐T cell therapy, its clinical efficacy has been greatly hampered by the high relapse rate. In this study, we designed and compared four structures of CD19/CD22 bispecific CAR‐T cells with different linkers and different orders of the antibody sequences.Methods: We detected the cytotoxicity, cytokine secretion levels, sustainable killing ability, differentiation, exhaustion of these four CAR‐T cells in vitro. The optimal Bis‐C CAR‐T cells were evaluated the efficacy using NSG mice.Results: The two structures of CD19/CD22 bispecific CAR‐T cells using (EAAAK)3 as linker had more significant cytotoxicity and cytokine secretion levels. In the process of continuous killing, Bis‐C CAR‐T cells showed better sustained killing ability, memory phenotype differentiation, and exhaustion. In the in vivo experiment mimicking CD19‐negative relapse, Bis‐C CAR‐T was more able to control the tumor progression of mice in the CD19 low expression or no expression groups than CD19 CAR‐T.Conclusions: This study has generated a novel bispecific CAR‐T cell that can simultaneously target CD19 or CD22 positive tumor cells, providing a new strategy to address the limitations of single‐targeted CAR‐T therapy in B‐cell tumors (limited response or relapse).
- 6 September 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (1) , 64-74
Open AccessEnhanced efficacy of CD19/CD22 bispecific CAR‐T cells with EAAAK linker on B‐cell malignancies
Objectives: Despite the great success of CD19 CAR‐T cell therapy, its clinical efficacy has been greatly hampered by the high relapse rate. In this study, we designed and compared four structures of CD19/CD22 bispecific CAR‐T cells with different linkers and different orders of the antibody sequences.Methods: We detected the cytotoxicity, cytokine secretion levels, sustainable killing ability, differentiation, exhaustion of these four CAR‐T cells in vitro. The optimal Bis‐C CAR‐T cells were evaluated the efficacy using NSG mice.Results: The two structures of CD19/CD22 bispecific CAR‐T cells using (EAAAK)3 as linker had more significant cytotoxicity and cytokine secretion levels. In the process of continuous killing, Bis‐C CAR‐T cells showed better sustained killing ability, memory phenotype differentiation, and exhaustion. In the in vivo experiment mimicking CD19‐negative relapse, Bis‐C CAR‐T was more able to control the tumor progression of mice in the CD19 low expression or no expression groups than CD19 CAR‐T.Conclusions: This study has generated a novel bispecific CAR‐T cell that can simultaneously target CD19 or CD22 positive tumor cells, providing a new strategy to address the limitations of single‐targeted CAR‐T therapy in B‐cell tumors (limited response or relapse).